Earnings Call Summary | Helius Medical Technologies(HSDT.US) Q1 2024 Earnings Conference
Earnings Call Summary | Helius Medical Technologies(HSDT.US) Q1 2024 Earnings Conference
The following is a summary of the Helius Medical Technologies, Inc. (HSDT) Q1 2024 Earnings Call Transcript:
以下是Helius Medical Technologies, Inc.(HSDT)2024年第一季度财报电话会议记录摘要:
Financial Performance:
财务业绩:
Helius reported a Q1 2024 total revenue of $135,000, up from $111,000 in Q1 2023.
Cost of revenue remained similar to the previous year at $123,000.
Selling, general, and administrative expenses declined to $2.6 million mainly due to a decrease in professional fees and payroll-related overheads.
Research and development expenses decreased to $0.8 million as the company shifted focus to U.S. commercialization activities.
The operating loss was down to $3.4 million, with a net loss of $2.5 million.
Closed a $6.4 million public offering in May 2024 to extend the company's cash runway.
Helius报告称,2024年第一季度的总收入为13.5万美元,高于2023年第一季度的11.1万美元。
收入成本与上年相似,为12.3万美元。
销售、一般和管理费用下降至260万美元,这主要是由于专业费用和与工资相关的管理费用减少。
由于公司将重点转移到美国的商业化活动上,研发费用降至80万美元。
营业亏损降至340万美元,净亏损250万美元。
2024 年 5 月完成了 640 万澳元的公开募股,以延长公司的现金流。
Business Progress:
业务进展:
Focus on securing widespread reimbursement for PoNS and achieving FDA approval for stroke.
CMS established HCPCS codes for the PoNS, facilitating negotiations with third-party payers.
Partnering with Global Government Services to widen accessibility to PoNS within federal healthcare systems.
Establishing sites in five separate Canadian regions to validate PoNS therapy for stroke patients.
Anticipating a positive impact on revenues and cash flow from the final determination of payment rates, effective October 1, 2024.
专注于确保PON的广泛报销,并获得美国食品药品管理局对中风的批准。
CMS为PON制定了HCPCS代码,促进了与第三方付款人的谈判。
与全球政府服务部门合作,扩大联邦医疗系统内PON的可及性。
在加拿大五个不同的地区建立站点,以验证中风患者的PoNs疗法。
预计最终确定付款率将对收入和现金流产生积极影响,自2024年10月1日起生效。
More details: Helius Medical Technologies IR
更多详情: Helius 医疗科技 IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:本文由 AI 生成。无法完全保证内容的准确性。欲了解更多详情,请访问投资者关系网站。本文仅供投资者参考,不构成任何投资建议。